zxclear

zxclear

[KR-바이오] 08/13 Korea Market Insights

삼성바이오로직스호재 As a senior equity analyst, my evaluation of Samsung Biologics (207940.KS) is anchored by its robust Q2 financial performance and strategic technological advancements. According to recent disclosures, the company delivered a strong second-quarter performance with (revenue of KRW 1.32…

[KR-플랫폼] 08/10 Korea Market Insights

NAVER호재 As a senior equity analyst, the recent strategic developments surrounding NAVER highlight a transformative pivot in the company’s valuation framework. The standout news is (NAVER, 엔비디아 투자로 입증한 AI 팩토리 사업 가치), which underscores NAVER’s successful foray into the…